Audien has quickly emerged as a category leader in the OTC hearing aid market by developing sleek, nearly invisible in-ear ...

Following completion of the dose escalation phase in relapsed/refractory acute leukemia patients with FLT3 mutations, Biomea ...

The Company is quickly advancing both its Marijuana Breath Test (MBT) with key validation work established in March, and its ...

Medical Advisory Board additions support company’s growing product offerings across women’s health and family building. NEW ...

Inozyme recently featured new clinical insights and hosted an educational symposium at the Joint Congress of the European ...

Sight Sciences’ management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life ...

Nasdaq BioCardia Reports First Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and ...

Alumis received an upfront license fee of $20.0 million in March 2025 and will receive an additional $20.0 million in near-term co-development payments, with potential for additional milestone ...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: ...

In March 2025, the European Patent Office issued a Notice of Allowance for a new patent application (European Patent Appl. No. 20798130.9) covering key aspects of BioRestorative’s allogeneic, ...

Clearside’s Asia-Pacific collaboration partner, Arctic Vision, announced that its New Drug Application (NDA) for ARCATUS ® (known as XIPERE ® in the U.S.) was formally accepted for review by the ...